Meta-analysis of laboratory results in patients with severe coronavirus disease 2019

xlomafota13 shared this article with you from Inoreader Meta-analysis of laboratory results in patients with severe coronavirus disease 2019 Via Experimental and therapeutic medicine Exp Ther Med. 2021 May;21(5):449. doi: 10.3892/etm.2021.9877. Epub 2021 Mar 1. ABSTRACT The aim of the present study was to analyze the differences in laboratory results between patients with severe and moderate coronavirus disease 2019 (COVID-19) for clinical intervention. The laboratory results of patients with COVID-19 between December 2019 and May 2020 were assembled from the Medline, Embase and Cochrane Library databases. A meta-analysis was conducted, calculating the individual and pooled odds ratios (ORs) with relative 95% confidence intervals (95% CIs) using Review Manager 5.3. The available data of 1,534 patients from 6 studies were included in this analysis. The results demonstrated that the incidence of leukocytosis, lymphocytopenia, increased procalcitonin (PCT), C-reactive protein (CRP), aspartate aminotransferase (AST) and lactic dehydrogenase (LDH) levels was associated with a nearly 3-fold (OR=3.44; 95% CI: 2.15-5.49), 4-fold (OR=4.39; 95% CI: 1.82-10.60), 5-fold (OR=5.28; 95% CI: 3.42-8.15), 4-fold (OR=3.99; 95% CI: 2.61-6.12), 3-fold (OR=3.02; 95% CI: 2.13-4.26) and 8-fold (OR=8.33; 95% CI: 1.75-39.69) higher risk of severe COVID-19 infection, respectively. These findings indicated that serial white blood cell count, lymphocyte count, CRP, PCT, LDH and AST measurements may be useful for predicting progression towards a more severe form of COVID-19. PMID:33747184 | PMC:PMC7967851 | DOI:10.3892/etm.2021.9877 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.